The USG seeks information from stakeholders on available medical countermeasures in development. BARDA is particularly interested in products, technologies, and capabilities that have progressed into or beyond clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform.
These requests are for market research purposes only and are not considered submissions for potential funding.
The Easy Broad Agency Announcement (EZ-BAA) sets forth areas of interest (AOIs) for the Division of Research, Innovation, and Ventures (DRIVe) and seeks abstracts for efforts to develop revolutionary health security products, technologies, and innovations in order to increase the Government’s capability and capacity to respond to national security health threats.
The EZ-BAA is for projects aligned with open AOIs, total funding under $750,000, and including a cost-share element. Respondents who have received an award under the EZ-BAA also have an opportunity to apply to the Plus (+) Phase of the EZ-BAA which allows for an additional award valued up to $20 million.
BARDA’s Broad Agency Announcement (BAA) solicits proposals for the advanced research and development of medical countermeasures (MCMs) such as vaccines, therapeutics, diagnostics, and devices. The BAA is intended for advanced research and development of MCMs to counter chemical, biological, radiological, and nuclear threats; pandemic influenza; and emerging infectious diseases.
The BAA is for projects aligned with open Areas of Interest (AOIs) specific to the solicitation.
BARDA's portal for file exchange and sharing. Access is limited to funded partners and collaborators.
Existing funded partners and collaborators use this portal to upload contract deliverables, project updates, and other relevant documentation.